January 13, 2012 -- A valuable indication of the peer-led international esteem accorded to innovative Glasgow-based drug solutions company Drug Delivery International (DDi) has been given by an invitation to founder Professor Howard Stevens to speak at a global drug delivery and formulation events.
Professor Stevens, who will be accompanied by DDi chief operating officer Dr Carol Thomson, will deliver an address at the Third Annual World Drug Delivery and Formulation Summit which is being held at the Maritim ProArte Hotel in Berlin from Monday to Wednesday (January 16 to 18).
The invitation, which highlights the reputation of the DDi team, opens new doors for the company at the Summit, which brings together scientific and business leaders in the field of drug delivery and promotes networking and ideas exchange.
In his address, Professor Stevens, who has more than 40 years' experience of management and research, will explore the relationships between industry and academics and provide understandings about how to make these relationships work.
Dr Thomson, who has been with DDi since its inception, said: "DDi is delighted to be represented at this world summit alongside some of the biggest names in the Pharma Industry
"At a time when many companies are seeking to optimise formulation and delivery and are questioning the 'blockbuster' model within the industry, the invitation is a clear validation of the value of what DDi is doing."
Professor Stevens, a registered pharmacist, has been involved in the formation of several successful spin-out businesses and served as the Pfizer Professor of Drug Delivery at the University of Strathclyde from 1998-2009.
He has an extensive scientific and patent publication record, is a fellow of the RPSGB, RSC and APSGB and served as Chairman of the APSGB in 2001.
Dr Thomson developed strong operational management skills at Thomson Reuters, where she managed the Pharmaceutical Patents Business Unit of the World Patents Index. She spent three years at the University of Strathclyde in a Research Business Development role and subsequently as Research Policy Manager.
Drug Delivery International, whose management team combines 120 years' experience in life science, has already seized the chance to license three University of Strathclyde patents with the potential to create significant medical benefits across the world.
DDi – sister company of Bio-Images Research, which last year announced a major expansion into Asia – plans to further develop the technologies for licensing to pharmaceutical or generic companies and is actively seeking to become involved in collaborative research with interested parties.
Its most recent patents are in the area of controlled drug release and have been demonstrated in the therapeutic areas of cardiovascular disease, pain management and sleep. As a result of the licensing agreement, DDI has already entered into early stage discussions with a global pharmaceutical company to secure a collaborative research agreement with an option to license a controlled release drug formulation for pain control.
For more information, please contact Dr Carol Thomson of Drug Delivery International on 0141 552 8791 or email@example.com